Leiden Biotech Cantoni针对NNMT募集肥胖药物资金, Leiden biotech Cantoni raises funds for obesity drug targeting NNMT, showing promise in fat reduction and energy boost.

Leiden大学的一家生物技术公司Cantoni治疗技术公司已筹集资金,以向NNMT(一种与新陈代谢疾病有关的蛋白质)提供非Incretin肥胖性药物。 Cantoni Therapeutics, a biotech firm from Leiden University, has raised funding to advance its non-incretin obesity drug targeting NNMT, a protein linked to metabolic diseases. 在布拉班特开发署、天使投资者和布拉班特启动基金的支持下,由Libertatis Ergo控股公司牵头的这一融资将推动该药物进入IND扶持型研究。 The financing, led by Libertatis Ergo Holding with support from Brabant Development Agency, angel investors, and the Brabant Startup Fund, will push the drug into IND-enabling studies. 该公司还获得了诺沃·诺迪斯克认证赠款,以支持关于NNMT在心肺健康方面的作用的研究。 The company also received a Novo Nordisk validation grant to support research on NNMT’s role in cardiometabolic health. 早期数据显示,该药物可以减少脂肪重量,不会伤害精瘦组织,并增加能量支出。 Early data show the drug reduces fat mass without harming lean tissue and boosts energy expenditure.